Treatment with IL-33R neutralizing antibodies has been shown to alleviate these inflammatory and fibrotic changes, suggesting that targeting the IL-33/IL-33R axis may represent a novel therapeutic approach for PF (Yi et al., 2022). The gene discussed is IL33; the disease is pemphigus foliaceus.